AI-researched · adversarially reviewed · human-checked · corrections public
BEFORE YOU READ — HOW DO YOU RULE?
The Verdict
If you are having a heart attack, a stent can save your life — that is settled and this page is not about it. If you have stable chest pain, three landmark trials across fifteen years keep finding the same thing: stents do not prevent heart attacks or death compared with good medication — and in blinded testing their symptom benefit shrank dramatically. Yet stable patients are still stented at scale, because the procedure pays well and "we opened the blockage" sells itself.
Oversold
STRONG EVIDENCE
§ What it actually does
Where the evidence says yes
strongSaves lives and heart muscle in heart attacks and unstable angina — emergency stenting is one of modern medicine's genuine triumphs.
moderateRelieves stable angina symptoms faster than medication alone in unblinded comparisons.
moderateLikely provides real symptom relief for stable angina in patients NOT on anti-anginal medication — the blinded ORBITA-2 trial found a genuine (modest) effect there.
§ What it doesn't do
Where the marketing outruns the data
contradictedDoes not prevent heart attacks or death in stable coronary disease, despite how it is routinely sold — COURAGE (2007), ISCHEMIA (2020), and meta-analyses agree.
strongDoes not "fix the plumbing": most future heart attacks arise from plaques that were NOT the tightest blockage on the angiogram. Stenting the visible narrowing does not defuse the artery.
strongIn patients already on good medication, blinded testing (ORBITA, 2017) found the symptom benefit over a placebo procedure was far smaller than everyone assumed.
§ The Money Map
Who profits, stage by stage
The procedureA stent placement bills thousands of dollars (US) and is a major private-hospital revenue line in India. The cath lab is capital equipment that must stay busy.
The reflexCardiologists themselves named it the "oculostenotic reflex": see a narrowing, stent it. The angiogram creates its own demand — every scan is a sales funnel for the procedure that follows.
The incentive gradientThe doctor who recommends the stent is very often the doctor who performs and bills it — a same-visit conflict most patients never register. Documented cases exist of cardiologists doing hundreds of unnecessary stents.
The honest contrastThe alternative — medication + cardiac rehab — pays almost nobody. No device markup, no procedure fee. Guess which one gets the glossy patient brochure.
This pageNo device money, no hospital sponsorship. See "How we make money."
§ The other side
The strongest case against this verdict
The strongest case against our verdict: trials enroll selected, protocol-managed patients, and their "optimal medical therapy" is better than what most real-world patients actually receive and adhere to. For a patient who cannot or will not take four drugs reliably, a one-time mechanical fix has practical value the trials undercount. ISCHEMIA also showed stenting improved symptoms and quality of life for the more symptomatic patients — relief from daily chest pain is not nothing, even if lifespan is unchanged. And revascularization decisions in left-main and severe multivessel disease genuinely differ — the skeptical headline must not leak into the anatomy where intervention still wins.
§ Symmetric harms
Harms of using it — and of avoiding it
If you use it
Procedure risks: bleeding, artery dissection, stroke, kidney injury from contrast — low single-digit percentages, but real, for a procedure that may add nothing.
Dual antiplatelet therapy for months–year after: bleeding risk for the duration.
Stent thrombosis: rare, sudden, and serious — a risk you acquire the moment the metal goes in.
False cure psychology: "I'm fixed" reliably erodes the medication adherence and lifestyle change that actually alter outcomes.
If you avoid it
In a heart attack or unstable symptoms: refusing emergency stenting is potentially fatal. This entire verdict is about STABLE disease.
Refusing the medication arm too — statins, blood-pressure control — abandons the part that actually prevents heart attacks.
Left-main or severe multivessel disease: revascularization (often surgery) has genuine benefit; blanket stent-refusal is as evidence-free as blanket stenting.
§ The Minority Report
Who gets hurt when it goes right for everyone else
The hurt minority here is unusual: it is the MAJORITY of stable patients receiving a procedure that could not help them — plus the small group seriously harmed by it.
Stable, medically-managed patients stented anyway: they absorb 100% of the procedural risk and the bleeding tail of antiplatelet therapy for a benefit trials cannot find.
The ~1–2% with serious procedural complications: for an unnecessary procedure, every one of these harms is fully attributable to the decision, not the disease.
Patients with kidney disease: contrast-induced kidney injury from angiography+PCI they may not have needed.
Anyone whose "blockage" was found by an unnecessary screening angiogram in the first place — the cascade started one test earlier.
How to tell if you might be in this group: Ask one question first: "Am I stable, or is this an emergency?" If stable, ask: "What do COURAGE and ISCHEMIA imply for someone like me — and can we try three months of full medical therapy first?"
§ The alternatives ledger
Everything else, judged by the same standards
strong
Optimal medical therapy (statin, BP control, antianginals, aspirin as indicated) The evidence-backed default for stable disease: same survival as stenting in trials, none of the procedural risk.
strong
Cardiac rehab / structured exercise Almost certainly reduces mortality after cardiac events and improves angina — the most under-prescribed intervention in cardiology, because nobody profits from it.
strong
Bypass surgery (CABG) for specific anatomy For left-main and severe multivessel disease (especially with diabetes), surgery retains genuine outcome benefits. Anatomy decides, not ideology.
none
EECP and chelation-style "artery cleaning" clinics There is no evidence chelation clears arteries; it is the wellness-industry mirror of the stent reflex — a different party profiting from the same plumbing story.
§ Take it to a human
Questions for your doctor
Am I stable? If yes: what happens if we try optimal medication for 3 months first?
Will the doctor recommending this stent also be performing and billing it?
What exactly will this stent change for my risk of heart attack or death — can you show me the trial?
Is my anatomy one of the cases (left-main, multivessel + diabetes) where revascularization genuinely wins?
How well trial-grade medical therapy is replicated in ordinary practice — the strongest pro-stent argument lives in this gap.
Long-term outcomes of the newest stent generations in stable disease (trials lag the hardware).
§ Corrections
Updates & corrections — public, dated, proud
No corrections yet. Found an error? Challenge it — substantiated challenges are corrected within 48 hours and logged here permanently. Submit a challenge →
§ We dissect ourselves too
How WE make money
This pageNo device manufacturers, no hospitals, no cath-lab advertising on this page. Health.AI earns from optional Pro subscriptions. If that changes, this box changes first.
Demand the next dissection
Any disease, drug, supplement, or practice. The queue decides what we dissect next.